Amgen files reply in support of quick appeal in CareFirst’s US case over Enbrel
( November 10, 2025, 23:31 GMT | Official Statement) -- MLex Summary: Amgen filed a reply supporting its petition to certify for immediate appeal CareFirst’s case accusing it of unlawfully delaying competition for its drug Enbrel after Amgen’s motion to dismiss was denied. “Plaintiffs do not dispute that antitrust cases in general are unusually complex compared to most litigation or that this case is likely to be especially burdensome. And Plaintiffs provide no reason why it would be a bad idea to give the court of appeals the opportunity to issue a decision that avoids or minimizes these burdens,” it argued. See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.